Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer

Documenti analoghi

• Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
  di: Jeremy Cheng, et al.
  Pubblicazione: (2025)
• A population‐based analyses of the evolving management of cN1M0 prostate cancer in the PSMA‐PET era
  di: Jennifer Ward, et al.
  Pubblicazione: (2025)
• Bibliometric analysis of focal therapy in prostate cancer research
  di: Mohammed Shahait, et al.
  Pubblicazione: (2024)
• Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
  di: Eric Margolis, et al.
  Pubblicazione: (2025)
• MRI performance to identify clinically significant prostate cancer following focal cryo‐ablation
  di: Herbert Lepor, et al.
  Pubblicazione: (2025)